Recently, immunotherapeutic agents such as immune checkpoint, histone deacetylase (HDAC), MAPK pathway, and TGFβ inhibitors have been used in combination with oHSVs, inducing an antitumor immune response and achieving a higher efficacy in targeted cancer cells, as shown in Table 1 [6,96,97,98]. This evidence concerns the gene TGFB1 and cancer.